O	O	O	0	6	Signal	Signal	B-NP	NN	O	3	NMOD	O
O	O	O	7	19	transduction	transduction	I-NP	NN	O	3	NMOD	O
O	O	O	20	33	abnormalities	abnormality	I-NP	NNS	O	17	NMOD	O
O	O	O	34	36	in	in	B-PP	IN	O	3	NMOD	O
O	O	O	37	38	T	T	B-NP	NN	B-cell_type	6	NMOD	B-cell_type
O	O	O	39	50	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	4	PMOD	I-cell_type
O	O	O	51	55	from	from	B-PP	IN	O	6	NMOD	O
O	O	O	56	64	patients	patient	B-NP	NNS	O	7	PMOD	O
O	O	O	65	69	with	with	B-PP	IN	O	8	NMOD	O
O	O	O	70	78	advanced	advance	B-NP	VBN	O	12	NMOD	O
O	O	O	79	84	renal	renal	I-NP	JJ	O	12	NMOD	O
O	O	O	85	94	carcinoma	carcinoma	I-NP	NN	O	9	PMOD	O
O	O	O	94	95	:	:	O	:	O	3	P	O
O	O	O	96	104	clinical	clinical	B-NP	JJ	O	15	NMOD	O
O	O	O	105	114	relevance	relevance	I-NP	NN	O	17	NMOD	O
O	O	O	115	118	and	and	O	CC	O	17	NMOD	O
O	O	O	119	126	effects	effect	B-NP	NNS	O	0	ROOT	O
O	O	O	127	129	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	130	138	cytokine	cytokine	B-NP	NN	B-protein	20	NMOD	B-protein
O	O	O	139	146	therapy	therapy	I-NP	NN	O	18	PMOD	O
O	O	O	146	147	.	.	O	.	O	17	P	O

O	O	O	149	156	Studies	Study	B-NP	NNS	O	2	SUB	O
O	O	O	157	161	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	162	174	demonstrated	demonstrate	I-VP	VBN	O	2	VC	O
O	O	O	175	188	abnormalities	abnormality	B-NP	NNS	O	18	NMOD	O
O	O	O	189	191	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	192	195	the	the	B-NP	DT	O	13	NMOD	O
T29	B-Entity	B-Entity	196	199	CD3	CD3	I-NP	NN	B-protein	13	NMOD	B-protein
T29	I-Entity	I-Entity	199	200	/	/	B-NP	SYM	O	13	P	O
T29	I-Entity	I-Entity	200	201	T	T	I-NP	NN	B-protein	13	NMOD	B-protein
T29	I-Entity	I-Entity	201	202	-	-	I-NP	HYPH	I-protein	13	NMOD	I-protein
T29	I-Entity	I-Entity	202	206	cell	cell	I-NP	NN	I-protein	13	NMOD	I-protein
T29	I-Entity	I-Entity	207	214	antigen	antigen	I-NP	NN	I-protein	13	NMOD	I-protein
T29	I-Entity	I-Entity	215	223	receptor	receptor	I-NP	NN	I-protein	5	PMOD	I-protein
T29	I-Entity	I-Entity	224	225	(	(	O	(	O	16	DEP	O
T29	I-Entity	I-Entity	225	228	TCR	TCR	B-NP	NN	B-protein	16	DEP	B-protein
T29	I-Entity	I-Entity	228	229	)	)	O	)	O	13	NMOD	O
O	O	O	230	233	and	and	O	CC	O	18	NMOD	O
O	O	O	234	242	pathways	pathway	B-NP	NNS	O	3	OBJ	O
O	O	O	243	245	of	of	B-PP	IN	O	18	NMOD	O
O	O	O	246	252	signal	signal	B-NP	NN	O	21	NMOD	O
O	O	O	253	265	transduction	transduction	I-NP	NN	O	19	PMOD	O
O	O	O	266	268	in	in	B-PP	IN	O	21	NMOD	O
O	O	O	269	270	T	T	B-NP	NN	B-cell_type	24	NMOD	B-cell_type
O	O	O	271	282	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	22	PMOD	I-cell_type
O	O	O	283	287	from	from	B-PP	IN	O	24	NMOD	O
O	O	O	288	295	animals	animal	B-NP	NNS	O	28	NMOD	O
O	O	O	296	299	and	and	O	CC	O	28	NMOD	O
O	O	O	300	308	patients	patient	B-NP	NNS	O	25	PMOD	O
O	O	O	309	313	with	with	B-PP	IN	O	28	NMOD	O
O	O	O	314	322	advanced	advanced	B-NP	JJ	O	31	NMOD	O
O	O	O	323	333	malignancy	malignancy	I-NP	NN	O	29	PMOD	O
O	O	O	333	334	.	.	O	.	O	2	P	O

O	O	O	335	345	Diminished	Diminish	B-NP	VBN	O	2	NMOD	O
O	O	O	346	356	expression	expression	I-NP	NN	O	30	SUB	O
O	O	O	357	359	of	of	B-PP	IN	O	2	NMOD	O
T1	B-Protein	B-Protein	360	367	TCRzeta	TCRzeta	B-NP	NN	B-protein	8	NMOD	B-protein
O	O	O	368	371	and	and	O	CC	O	8	NMOD	O
T2	B-Protein	B-Protein	372	375	p56	p56	B-NP	NN	B-protein	8	NMOD	B-protein
T2	I-Protein	I-Protein	375	376	(	(	O	(	I-protein	8	NMOD	I-protein
T2	I-Protein	I-Protein	376	379	lck	lck	B-NP	NN	I-protein	3	PMOD	I-protein
T2	I-Protein	I-Protein	379	380	)	)	O	)	I-protein	8	NMOD	I-protein
O	O	O	381	385	that	that	B-NP	WDT	O	8	NMOD	O
O	O	O	386	389	are	be	B-VP	VBP	O	10	SBAR	O
O	O	O	390	400	associated	associate	I-VP	VBN	O	11	VC	O
O	O	O	401	405	with	with	B-PP	IN	O	12	VMOD	O
O	O	O	406	409	the	the	B-NP	DT	O	15	NMOD	O
T30	B-Entity	B-Entity	410	413	TCR	TCR	I-NP	NN	B-protein	19	NMOD	B-protein
O	O	O	414	417	and	and	O	CC	O	19	NMOD	O
O	O	O	418	425	reduced	reduce	B-NP	VBN	O	19	NMOD	O
O	O	O	426	433	nuclear	nuclear	I-NP	JJ	O	19	NMOD	O
O	O	O	434	446	localization	localization	I-NP	NN	O	13	PMOD	O
O	O	O	447	449	of	of	B-PP	IN	O	19	NMOD	O
T3	B-Protein	B-Protein	450	454	RelA	RelA	B-NP	NN	B-protein	20	PMOD	B-protein
T31	B-Entity	B-Entity	455	465	containing	contain	B-VP	VBG	O	21	NMOD	O
T31	I-Entity	I-Entity	466	473	nuclear	nuclear	B-NP	JJ	B-protein	25	NMOD	B-protein
T31	I-Entity	I-Entity	474	480	factor	factor	I-NP	NN	I-protein	25	NMOD	I-protein
T31	I-Entity	I-Entity	481	487	kappaB	kappaB	I-NP	NN	I-protein	29	NMOD	I-protein
T31	I-Entity	I-Entity	488	489	(	(	O	(	O	29	NMOD	O
T31	I-Entity	I-Entity	489	497	NFkappaB	NFkappaB	B-NP	NN	B-protein	29	NMOD	B-protein
T31	I-Entity	I-Entity	497	498	)	)	O	)	O	29	NMOD	O
T31	I-Entity	I-Entity	499	508	complexes	complex	B-NP	NNS	O	22	OBJ	O
O	O	O	509	513	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	514	518	been	be	I-VP	VBN	O	30	VC	O
O	O	O	519	524	noted	note	I-VP	VBN	O	31	VC	O
O	O	O	524	525	.	.	O	.	O	30	P	O

O	O	O	526	531	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	532	539	defects	defect	I-NP	NNS	O	3	SUB	O
O	O	O	540	544	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	545	549	been	be	I-VP	VBN	O	3	VC	O
O	O	O	550	559	described	describe	I-VP	VBN	O	4	VC	O
O	O	O	560	562	in	in	B-PP	IN	O	5	VMOD	O
O	O	O	563	564	T	T	B-NP	NN	B-cell_type	8	NMOD	B-cell_type
O	O	O	565	570	cells	cell	I-NP	NNS	I-cell_type	6	PMOD	I-cell_type
O	O	O	571	575	from	from	B-PP	IN	O	8	NMOD	O
O	O	O	576	584	patients	patient	B-NP	NNS	O	9	PMOD	O
O	O	O	585	589	with	with	B-PP	IN	O	10	NMOD	O
O	O	O	590	599	malignant	malignant	B-NP	JJ	O	13	NMOD	O
O	O	O	600	608	melanoma	melanoma	I-NP	NN	O	11	PMOD	O
O	O	O	608	609	,	,	O	,	O	3	P	O
O	O	O	610	615	renal	renal	B-NP	JJ	O	17	NMOD	O
O	O	O	616	620	cell	cell	I-NP	NN	O	17	NMOD	O
O	O	O	621	630	carcinoma	carcinoma	I-NP	NN	O	27	NMOD	O
O	O	O	631	632	(	(	O	(	O	20	DEP	O
O	O	O	632	635	RCC	RCC	B-NP	NN	O	20	DEP	O
O	O	O	635	636	)	)	O	)	O	17	NMOD	O
O	O	O	636	637	,	,	O	,	O	27	P	O
O	O	O	638	645	ovarian	ovarian	B-NP	JJ	O	23	NMOD	O
O	O	O	646	652	cancer	cancer	I-NP	NN	O	27	NMOD	O
O	O	O	652	653	,	,	O	,	O	27	P	O
O	O	O	654	657	and	and	O	CC	O	27	NMOD	O
O	O	O	658	668	colorectal	colorectal	B-NP	JJ	O	27	NMOD	O
O	O	O	669	675	cancer	cancer	I-NP	NN	O	3	VMOD	O
O	O	O	675	676	.	.	O	.	O	3	P	O

O	O	O	677	688	Preliminary	Preliminary	B-NP	JJ	O	2	NMOD	O
O	O	O	689	701	observations	observation	I-NP	NNS	O	4	SUB	O
O	O	O	702	706	also	also	B-ADVP	RB	O	4	VMOD	O
O	O	O	707	715	indicate	indicate	B-VP	VBP	O	0	ROOT	O
O	O	O	716	724	possible	possible	B-NP	JJ	O	6	NMOD	O
O	O	O	725	736	correlation	correlation	I-NP	NN	O	4	OBJ	O
O	O	O	737	741	with	with	B-PP	IN	O	6	NMOD	O
O	O	O	742	750	clinical	clinical	B-NP	JJ	O	9	NMOD	O
O	O	O	751	760	variables	variable	I-NP	NNS	O	7	PMOD	O
O	O	O	761	765	such	such	B-PP	JJ	O	11	PMOD	O
O	O	O	766	768	as	as	I-PP	IN	O	9	NMOD	O
O	O	O	769	774	stage	stage	B-NP	NN	O	11	PMOD	O
O	O	O	775	777	in	in	B-PP	IN	O	12	NMOD	O
O	O	O	778	786	selected	select	B-NP	VBN	O	15	NMOD	O
O	O	O	787	796	instances	instance	I-NP	NNS	O	13	PMOD	O
O	O	O	796	797	.	.	O	.	O	4	P	O

O	O	O	798	800	To	To	B-VP	TO	O	3	VMOD	O
O	O	O	801	808	further	further	I-VP	RB	O	3	VMOD	O
O	O	O	809	821	characterize	characterize	I-VP	VB	O	22	VMOD	O
O	O	O	822	829	altered	altered	B-NP	JJ	O	5	NMOD	O
O	O	O	830	840	expression	expression	I-NP	NN	O	3	OBJ	O
O	O	O	841	843	of	of	B-PP	IN	O	5	NMOD	O
T4	B-Protein	B-Protein	844	851	TCRzeta	TCRzeta	B-NP	NN	B-protein	11	NMOD	B-protein
O	O	O	851	852	,	,	O	,	O	11	P	O
T5	B-Protein	B-Protein	853	856	p56	p56	B-NP	NN	B-protein	11	NMOD	B-protein
T5	I-Protein	I-Protein	856	857	(	(	O	(	I-protein	11	NMOD	I-protein
T5	I-Protein	I-Protein	857	860	lck	lck	B-NP	NN	I-protein	6	PMOD	I-protein
T5	I-Protein	I-Protein	860	861	)	)	O	)	I-protein	11	NMOD	I-protein
O	O	O	861	862	,	,	O	,	O	22	P	O
O	O	O	863	866	and	and	O	CC	O	22	VMOD	O
O	O	O	867	875	impaired	impaired	B-NP	JJ	O	16	NMOD	O
O	O	O	876	886	activation	activation	I-NP	NN	O	22	SUB	O
O	O	O	887	889	of	of	B-PP	IN	O	16	NMOD	O
T32	B-Entity	B-Entity	890	898	NFkappaB	NFkappaB	B-NP	NN	B-protein	21	NMOD	B-protein
O	O	O	898	899	,	,	O	,	O	21	P	O
O	O	O	900	901	T	T	B-NP	NN	B-cell_type	21	NMOD	B-cell_type
O	O	O	902	913	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	17	PMOD	I-cell_type
O	O	O	914	918	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	919	927	obtained	obtain	I-VP	VBN	O	22	VC	O
O	O	O	928	932	from	from	B-PP	IN	O	23	VMOD	O
O	O	O	933	935	65	65	B-NP	CD	O	26	NMOD	O
O	O	O	936	944	patients	patient	I-NP	NNS	O	24	PMOD	O
O	O	O	945	949	with	with	B-PP	IN	O	26	NMOD	O
O	O	O	950	953	RCC	RCC	B-NP	NN	O	27	PMOD	O
O	O	O	953	954	,	,	O	,	O	22	P	O
O	O	O	955	958	the	the	B-NP	DT	O	31	NMOD	O
O	O	O	959	967	majority	majority	I-NP	NN	O	34	SUB	O
O	O	O	968	970	of	of	B-PP	IN	O	31	NMOD	O
O	O	O	971	975	whom	whom	B-NP	WP	O	32	PMOD	O
O	O	O	976	980	were	be	B-VP	VBD	O	22	VMOD	O
O	O	O	981	990	receiving	receive	I-VP	VBG	O	34	VC	O
O	O	O	991	1002	combination	combination	B-NP	NN	O	38	NMOD	O
O	O	O	1003	1011	cytokine	cytokine	I-NP	NN	B-protein	38	NMOD	B-protein
O	O	O	1012	1019	therapy	therapy	I-NP	NN	O	35	OBJ	O
O	O	O	1020	1021	[	[	O	(	O	43	DEP	O
T6	B-Protein	B-Protein	1021	1032	interleukin	interleukin	B-NP	NN	B-protein	42	NMOD	B-protein
T6	I-Protein	I-Protein	1033	1034	(	(	O	(	I-protein	42	NMOD	I-protein
T6	I-Protein	I-Protein	1034	1036	IL	IL	B-NP	NN	I-protein	43	DEP	I-protein
T6	I-Protein	I-Protein	1036	1037	)	)	O	)	I-protein	38	NMOD	I-protein
T6	I-Protein	I-Protein	1037	1038	-	-	B-NP	HYPH	I-protein	38	NMOD	I-protein
T6	I-Protein	I-Protein	1038	1039	2	2	I-NP	CD	I-protein	38	NMOD	I-protein
O	O	O	1039	1040	,	,	O	,	O	48	P	O
T7	B-Protein	B-Protein	1041	1044	IFN	IFN	B-NP	NN	B-protein	48	NMOD	B-protein
T7	I-Protein	I-Protein	1045	1050	alpha	alpha	O	SYM	I-protein	38	NMOD	I-protein
O	O	O	1050	1051	-	-	O	HYPH	O	38	P	O
O	O	O	1051	1061	containing	contain	B-VP	VBG	O	38	NMOD	O
O	O	O	1062	1070	regimens	regimen	B-NP	NNS	O	56	NMOD	O
O	O	O	1070	1071	]	]	O	)	O	56	NMOD	O
O	O	O	1072	1075	and	and	O	CC	O	56	NMOD	O
O	O	O	1076	1078	37	37	B-NP	CD	O	56	NMOD	O
O	O	O	1079	1086	control	control	I-NP	JJ	O	56	NMOD	O
O	O	O	1087	1098	individuals	individual	I-NP	NNS	O	50	OBJ	O
O	O	O	1098	1099	.	.	O	.	O	22	P	O

O	O	O	1100	1102	In	In	B-PP	IN	O	15	VMOD	O
O	O	O	1103	1105	29	29	B-NP	CD	O	1	PMOD	O
O	O	O	1106	1108	of	of	B-PP	IN	O	2	NMOD	O
O	O	O	1109	1114	these	these	B-NP	DT	O	5	NMOD	O
O	O	O	1115	1123	patients	patient	I-NP	NNS	O	3	PMOD	O
O	O	O	1123	1124	,	,	O	,	O	15	P	O
O	O	O	1125	1131	levels	level	B-NP	NNS	O	15	SUB	O
O	O	O	1132	1134	of	of	B-PP	IN	O	7	NMOD	O
T8	B-Protein	B-Protein	1135	1142	TCRzeta	TCRzeta	B-NP	NN	B-protein	13	NMOD	B-protein
O	O	O	1143	1146	and	and	O	CC	O	13	NMOD	O
T9	B-Protein	B-Protein	1147	1150	p56	p56	B-NP	NN	B-protein	13	NMOD	B-protein
T9	I-Protein	I-Protein	1150	1151	(	(	O	(	I-protein	13	NMOD	I-protein
T9	I-Protein	I-Protein	1151	1154	lck	lck	B-NP	NN	I-protein	8	PMOD	I-protein
T9	I-Protein	I-Protein	1154	1155	)	)	O	)	I-protein	13	NMOD	I-protein
O	O	O	1156	1160	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1161	1171	determined	determine	I-VP	VBN	O	15	VC	O
O	O	O	1172	1174	by	by	B-PP	IN	O	16	VMOD	O
O	O	O	1175	1182	Western	Western	B-NP	JJ	O	19	NMOD	O
O	O	O	1183	1188	blots	blot	I-NP	NNS	O	17	PMOD	O
O	O	O	1189	1191	of	of	B-PP	IN	O	19	NMOD	O
O	O	O	1192	1193	T	T	B-NP	NN	O	24	NMOD	O
O	O	O	1193	1194	-	-	I-NP	HYPH	O	24	NMOD	O
O	O	O	1194	1198	cell	cell	I-NP	NN	O	24	NMOD	O
O	O	O	1199	1206	lysates	lysate	I-NP	NNS	O	20	PMOD	O
O	O	O	1207	1210	and	and	O	CC	O	16	VMOD	O
O	O	O	1211	1226	semiquantitated	semiquantitate	B-VP	VBN	O	16	VMOD	O
O	O	O	1227	1232	using	use	B-VP	VBG	O	26	VMOD	O
O	O	O	1233	1245	densitometry	densitometry	B-NP	NN	O	27	OBJ	O
O	O	O	1245	1246	.	.	O	.	O	15	P	O

O	O	O	1247	1255	Relative	Relative	B-NP	JJ	O	2	NMOD	O
O	O	O	1256	1262	levels	level	I-NP	NNS	O	3	SUB	O
O	O	O	1263	1267	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1268	1272	then	then	I-VP	RB	O	3	VMOD	O
O	O	O	1273	1283	correlated	correlate	I-VP	VBN	O	3	VC	O
O	O	O	1284	1288	with	with	B-PP	IN	O	5	VMOD	O
O	O	O	1289	1290	a	a	B-NP	DT	O	8	NMOD	O
O	O	O	1291	1297	series	series	I-NP	NN	O	28	NMOD	O
O	O	O	1298	1300	of	of	B-PP	IN	O	8	NMOD	O
O	O	O	1301	1309	clinical	clinical	B-NP	JJ	O	11	NMOD	O
O	O	O	1310	1319	variables	variable	I-NP	NNS	O	9	PMOD	O
O	O	O	1320	1329	including	include	B-PP	VBG	O	11	NMOD	O
O	O	O	1330	1338	response	response	B-NP	NN	O	12	PMOD	O
O	O	O	1339	1341	to	to	B-PP	TO	O	13	NMOD	O
O	O	O	1342	1349	therapy	therapy	B-NP	NN	O	14	PMOD	O
O	O	O	1349	1350	,	,	O	,	O	28	P	O
O	O	O	1351	1362	performance	performance	B-NP	NN	O	18	NMOD	O
O	O	O	1363	1369	status	status	I-NP	NN	O	28	NMOD	O
O	O	O	1369	1370	,	,	O	,	O	28	P	O
O	O	O	1371	1379	survival	survival	B-NP	NN	O	28	NMOD	O
O	O	O	1379	1380	,	,	O	,	O	28	P	O
O	O	O	1381	1388	disease	disease	B-NP	NN	O	23	NMOD	O
O	O	O	1389	1394	sites	site	I-NP	NNS	O	28	NMOD	O
O	O	O	1394	1395	,	,	O	,	O	28	P	O
O	O	O	1396	1399	age	age	B-NP	NN	O	28	NMOD	O
O	O	O	1399	1400	,	,	O	,	O	28	P	O
O	O	O	1401	1404	and	and	O	CC	O	28	NMOD	O
O	O	O	1405	1411	others	other	B-NP	NNS	O	6	PMOD	O
O	O	O	1411	1412	.	.	O	.	O	3	P	O

O	O	O	1413	1415	In	In	B-PP	IN	O	22	VMOD	O
O	O	O	1416	1423	another	another	B-NP	DT	O	3	NMOD	O
O	O	O	1424	1429	group	group	I-NP	NN	O	1	PMOD	O
O	O	O	1430	1432	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	1433	1435	28	28	B-NP	CD	O	6	NMOD	O
O	O	O	1436	1444	patients	patient	I-NP	NNS	O	4	PMOD	O
O	O	O	1445	1446	(	(	O	(	O	14	DEP	O
O	O	O	1446	1451	three	three	B-NP	CD	O	9	NMOD	O
O	O	O	1452	1463	individuals	individual	I-NP	NNS	O	14	DEP	O
O	O	O	1464	1468	from	from	B-PP	IN	O	9	NMOD	O
O	O	O	1469	1472	the	the	B-NP	DT	O	13	NMOD	O
O	O	O	1473	1478	first	first	I-NP	JJ	O	13	NMOD	O
O	O	O	1479	1484	group	group	I-NP	NN	O	10	PMOD	O
O	O	O	1484	1485	)	)	O	)	O	1	PMOD	O
O	O	O	1485	1486	,	,	O	,	O	22	P	O
O	O	O	1487	1490	the	the	B-NP	DT	O	17	NMOD	O
O	O	O	1491	1500	frequency	frequency	I-NP	NN	O	22	SUB	O
O	O	O	1501	1503	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	1504	1512	abnormal	abnormal	B-NP	JJ	O	21	NMOD	O
T33	B-Entity	B-Entity	1513	1521	NFkappaB	NFkappaB	I-NP	NN	B-protein	21	NMOD	B-protein
O	O	O	1522	1532	activation	activation	I-NP	NN	O	18	PMOD	O
O	O	O	1533	1536	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1537	1544	studied	study	I-VP	VBN	O	22	VC	O
O	O	O	1545	1550	using	use	B-VP	VBG	O	22	VMOD	O
O	O	O	1551	1566	electrophoretic	electrophoretic	B-NP	JJ	O	28	NMOD	O
O	O	O	1567	1575	mobility	mobility	I-NP	NN	O	28	NMOD	O
O	O	O	1576	1581	shift	shift	I-NP	NN	O	28	NMOD	O
O	O	O	1582	1588	assays	assay	I-NP	NNS	O	24	OBJ	O
O	O	O	1589	1594	after	after	B-PP	IN	O	28	NMOD	O
O	O	O	1595	1605	activation	activation	B-NP	NN	O	29	PMOD	O
O	O	O	1606	1608	of	of	B-PP	IN	O	30	NMOD	O
O	O	O	1609	1610	T	T	B-NP	NN	B-cell_type	33	NMOD	B-cell_type
O	O	O	1611	1616	cells	cell	I-NP	NNS	I-cell_type	31	PMOD	I-cell_type
O	O	O	1617	1621	with	with	B-PP	IN	O	30	NMOD	O
O	O	O	1622	1629	phorbol	phorbol	B-NP	NN	O	39	NMOD	O
O	O	O	1630	1639	myristate	myristate	I-NP	NN	O	39	NMOD	O
O	O	O	1640	1647	acetate	acetate	I-NP	NN	O	39	NMOD	O
O	O	O	1647	1648	/	/	B-NP	SYM	O	39	NMOD	O
O	O	O	1648	1657	ionomycin	ionomycin	I-NP	NN	O	45	NMOD	O
O	O	O	1658	1660	or	or	O	CC	O	45	NMOD	O
O	O	O	1661	1665	anti	anti	B-NP	AFX	B-protein	45	NMOD	B-protein
O	O	O	1665	1666	-	-	I-NP	HYPH	I-protein	45	NMOD	I-protein
T34	B-Entity	B-Entity	1666	1669	CD3	CD3	I-NP	NN	I-protein	45	NMOD	I-protein
O	O	O	1670	1680	monoclonal	monoclonal	I-NP	JJ	I-protein	45	NMOD	I-protein
O	O	O	1681	1689	antibody	antibody	I-NP	NN	I-protein	34	PMOD	I-protein
O	O	O	1689	1690	.	.	O	.	O	22	P	O

O	O	O	1691	1698	Changes	Change	B-NP	NNS	O	9	SUB	O
O	O	O	1699	1701	in	in	B-PP	IN	O	1	NMOD	O
O	O	O	1702	1707	these	these	B-NP	DT	O	5	NMOD	O
O	O	O	1708	1717	signaling	signal	I-NP	VBG	B-protein	5	NMOD	B-protein
O	O	O	1718	1727	molecules	molecule	I-NP	NNS	I-protein	2	PMOD	I-protein
O	O	O	1728	1734	during	during	B-PP	IN	O	1	NMOD	O
O	O	O	1735	1743	cytokine	cytokine	B-NP	NN	B-protein	8	NMOD	B-protein
O	O	O	1744	1753	treatment	treatment	I-NP	NN	O	6	PMOD	O
O	O	O	1754	1758	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1759	1763	also	also	I-VP	RB	O	9	VMOD	O
O	O	O	1764	1776	investigated	investigate	I-VP	VBN	O	9	VC	O
O	O	O	1776	1777	.	.	O	.	O	9	P	O

T10	B-Protein	B-Protein	1778	1785	TCRzeta	TCRzeta	B-NP	NN	B-protein	5	NMOD	B-protein
O	O	O	1786	1789	and	and	I-NP	CC	O	5	NMOD	O
T11	B-Protein	B-Protein	1790	1793	p56	p56	I-NP	NN	B-protein	5	NMOD	B-protein
T11	I-Protein	I-Protein	1793	1794	(	(	O	(	I-protein	5	NMOD	I-protein
T11	I-Protein	I-Protein	1794	1797	lck	lck	B-NP	NN	I-protein	7	SUB	I-protein
T11	I-Protein	I-Protein	1797	1798	)	)	O	)	I-protein	5	NMOD	I-protein
O	O	O	1799	1803	were	be	B-VP	VBD	O	26	VMOD	O
O	O	O	1804	1812	detected	detect	I-VP	VBN	O	7	VC	O
O	O	O	1813	1815	in	in	B-PP	IN	O	8	VMOD	O
O	O	O	1816	1819	the	the	B-NP	DT	O	14	NMOD	O
O	O	O	1820	1830	peripheral	peripheral	I-NP	JJ	B-cell_type	14	NMOD	B-cell_type
O	O	O	1831	1836	blood	blood	I-NP	NN	I-cell_type	14	NMOD	I-cell_type
O	O	O	1837	1838	T	T	I-NP	NN	I-cell_type	14	NMOD	I-cell_type
O	O	O	1839	1844	cells	cell	I-NP	NNS	I-cell_type	9	PMOD	I-cell_type
O	O	O	1845	1847	in	in	B-PP	IN	O	8	VMOD	O
O	O	O	1848	1850	27	27	B-NP	CD	O	15	PMOD	O
O	O	O	1851	1853	of	of	B-PP	IN	O	16	NMOD	O
O	O	O	1854	1856	29	29	B-NP	CD	O	19	NMOD	O
O	O	O	1857	1865	patients	patient	I-NP	NNS	O	17	PMOD	O
O	O	O	1865	1866	,	,	O	,	O	26	P	O
O	O	O	1867	1870	and	and	O	CC	O	26	VMOD	O
O	O	O	1871	1878	overall	overall	B-ADVP	RB	O	26	VMOD	O
O	O	O	1878	1879	,	,	O	,	O	26	P	O
O	O	O	1880	1887	reduced	reduce	B-NP	VBN	O	25	NMOD	O
O	O	O	1888	1894	levels	level	I-NP	NNS	O	26	SUB	O
O	O	O	1895	1899	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1900	1905	noted	note	I-VP	VBN	O	26	VC	O
O	O	O	1906	1914	visually	visually	B-ADVP	RB	O	27	VMOD	O
O	O	O	1915	1917	in	in	B-PP	IN	O	27	VMOD	O
O	O	O	1918	1920	12	12	B-NP	CD	O	29	PMOD	O
O	O	O	1921	1923	of	of	B-PP	IN	O	30	NMOD	O
O	O	O	1924	1926	29	29	B-NP	CD	O	38	NMOD	O
O	O	O	1927	1928	(	(	O	(	O	36	DEP	O
O	O	O	1928	1930	41	41	B-NP	CD	O	35	NMOD	O
O	O	O	1930	1931	%	%	I-NP	NN	O	36	DEP	O
O	O	O	1931	1932	)	)	O	)	O	32	NMOD	O
O	O	O	1933	1936	and	and	O	CC	O	38	NMOD	O
O	O	O	1937	1939	13	13	B-NP	CD	O	31	PMOD	O
O	O	O	1940	1942	of	of	B-PP	IN	O	38	NMOD	O
O	O	O	1943	1945	29	29	B-NP	CD	O	45	NMOD	O
O	O	O	1946	1947	(	(	O	(	O	44	DEP	O
O	O	O	1947	1949	45	45	B-NP	CD	O	43	NMOD	O
O	O	O	1949	1950	%	%	I-NP	NN	O	44	DEP	O
O	O	O	1950	1951	)	)	O	)	O	40	NMOD	O
O	O	O	1952	1963	individuals	individual	B-NP	NNS	O	39	PMOD	O
O	O	O	1963	1964	,	,	O	,	O	27	P	O
O	O	O	1965	1977	respectively	respectively	B-ADVP	RB	O	27	VMOD	O
O	O	O	1977	1978	.	.	O	.	O	26	P	O

O	O	O	1979	1983	When	When	B-ADVP	WRB	O	47	VMOD	O
O	O	O	1984	1990	levels	level	B-NP	NNS	O	3	SUB	O
O	O	O	1991	1995	were	be	B-VP	VBD	O	1	SBAR	O
O	O	O	1996	2011	semiquantitated	semiquantitate	I-VP	VBN	O	3	VC	O
O	O	O	2012	2017	using	use	B-VP	VBG	O	1	SBAR	O
O	O	O	2018	2030	densitometry	densitometry	B-NP	NN	O	22	NMOD	O
O	O	O	2030	2031	,	,	O	,	O	22	P	O
O	O	O	2032	2043	significant	significant	B-NP	JJ	O	9	NMOD	O
O	O	O	2044	2053	decreases	decrease	I-NP	NNS	O	22	NMOD	O
O	O	O	2054	2056	of	of	B-PP	IN	O	9	NMOD	O
T12	B-Protein	B-Protein	2057	2064	TCRzeta	TCRzeta	B-NP	NN	B-protein	10	PMOD	B-protein
O	O	O	2065	2066	(	(	O	(	O	18	DEP	O
O	O	O	2066	2067	P	P	B-NP	NN	O	18	DEP	O
O	O	O	2068	2069	=	=	B-VP	SYM	O	13	NMOD	O
O	O	O	2070	2071	0	0	B-NP	CD	O	14	AMOD	O
O	O	O	2071	2072	.	.	O	.	O	13	P	O
O	O	O	2072	2075	029	029	B-NP	CD	O	13	NMOD	O
O	O	O	2075	2076	)	)	O	)	O	9	NMOD	O
O	O	O	2077	2080	and	and	O	CC	O	22	NMOD	O
T13	B-Protein	B-Protein	2081	2084	p56	p56	B-NP	NN	B-protein	22	NMOD	B-protein
T13	I-Protein	I-Protein	2084	2085	(	(	O	(	I-protein	22	NMOD	I-protein
T13	I-Protein	I-Protein	2085	2088	lck	lck	B-NP	NN	I-protein	33	NMOD	I-protein
T13	I-Protein	I-Protein	2088	2089	)	)	O	)	I-protein	22	NMOD	I-protein
O	O	O	2090	2091	(	(	O	(	O	30	DEP	O
O	O	O	2091	2092	P	P	B-NP	NN	O	29	NMOD	O
O	O	O	2093	2094	=	=	B-VP	SYM	O	25	NMOD	O
O	O	O	2095	2096	0	0	B-NP	CD	O	26	AMOD	O
O	O	O	2096	2097	.	.	O	.	O	29	P	O
O	O	O	2097	2100	029	029	B-NP	CD	O	30	DEP	O
O	O	O	2100	2101	)	)	O	)	O	22	NMOD	O
O	O	O	2102	2105	but	but	B-NP	CC	O	33	NMOD	O
O	O	O	2106	2109	not	not	I-NP	RB	O	31	DEP	O
T14	B-Protein	B-Protein	2110	2120	CD3epsilon	CD3epsilon	B-NP	NN	B-protein	5	OBJ	B-protein
O	O	O	2121	2122	(	(	O	(	O	40	DEP	O
O	O	O	2122	2123	P	P	B-NP	NN	O	39	SUB	O
O	O	O	2124	2125	=	=	B-VP	SYM	O	39	VMOD	O
O	O	O	2126	2127	0	0	B-NP	CD	O	39	AMOD	O
O	O	O	2127	2128	.	.	I-NP	SYM	O	39	AMOD	O
O	O	O	2128	2131	131	131	I-NP	CD	O	40	DEP	O
O	O	O	2131	2132	)	)	O	)	O	33	NMOD	O
O	O	O	2132	2133	,	,	O	,	O	33	P	O
O	O	O	2134	2142	compared	compare	B-PP	VBN	O	5	VMOD	O
O	O	O	2143	2147	with	with	B-PP	IN	O	42	PMOD	O
O	O	O	2148	2155	control	control	B-NP	NN	O	45	NMOD	O
O	O	O	2156	2162	levels	level	I-NP	NNS	O	43	PMOD	O
O	O	O	2162	2163	,	,	O	,	O	47	P	O
O	O	O	2164	2168	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	2169	2174	found	find	I-VP	VBN	O	47	VC	O
O	O	O	2174	2175	.	.	O	.	O	47	P	O

O	O	O	2176	2178	In	In	B-PP	IN	O	19	VMOD	O
O	O	O	2179	2187	patients	patient	B-NP	NNS	O	1	PMOD	O
O	O	O	2188	2195	treated	treat	B-VP	VBN	O	2	NMOD	O
O	O	O	2196	2200	with	with	B-PP	IN	O	3	VMOD	O
T15	B-Protein	B-Protein	2201	2203	IL	IL	B-NP	NN	B-protein	10	NMOD	B-protein
T15	I-Protein	I-Protein	2203	2204	-	-	B-NP	HYPH	I-protein	5	NMOD	I-protein
T15	I-Protein	I-Protein	2204	2205	2	2	I-NP	CD	I-protein	5	NMOD	I-protein
O	O	O	2205	2206	/	/	I-NP	SYM	O	10	P	O
T16	B-Protein	B-Protein	2206	2209	IFN	IFN	I-NP	NN	B-protein	10	NMOD	B-protein
T16	I-Protein	I-Protein	2210	2215	alpha	alpha	B-NP	SYM	I-protein	13	NMOD	I-protein
O	O	O	2215	2216	-	-	B-PP	HYPH	O	13	NMOD	O
O	O	O	2216	2221	based	base	B-NP	VBN	O	13	NMOD	O
O	O	O	2222	2229	therapy	therapy	I-NP	NN	O	4	PMOD	O
O	O	O	2229	2230	,	,	O	,	O	19	P	O
O	O	O	2231	2239	relative	relative	B-NP	JJ	O	16	NMOD	O
O	O	O	2240	2246	levels	level	I-NP	NNS	O	19	SUB	O
O	O	O	2247	2249	of	of	B-PP	IN	O	16	NMOD	O
T17	B-Protein	B-Protein	2250	2257	TCRzeta	TCRzeta	B-NP	NN	B-protein	17	PMOD	B-protein
O	O	O	2258	2267	increased	increase	B-VP	VBD	O	0	ROOT	O
O	O	O	2268	2281	significantly	significantly	B-ADVP	RB	O	19	VMOD	O
O	O	O	2282	2283	(	(	O	(	O	27	DEP	O
O	O	O	2283	2284	P	P	B-NP	NN	O	27	DEP	O
O	O	O	2285	2286	=	=	B-VP	SYM	O	22	NMOD	O
O	O	O	2287	2288	0	0	B-NP	CD	O	23	AMOD	O
O	O	O	2288	2289	.	.	O	.	O	22	P	O
O	O	O	2289	2292	002	002	B-NP	CD	O	22	NMOD	O
O	O	O	2292	2293	)	)	O	)	O	20	AMOD	O
O	O	O	2294	2296	on	on	B-PP	IN	O	19	VMOD	O
O	O	O	2297	2300	day	day	B-NP	NN	O	28	PMOD	O
O	O	O	2301	2303	15	15	I-NP	CD	O	29	NMOD	O
O	O	O	2304	2306	of	of	B-PP	IN	O	29	NMOD	O
O	O	O	2307	2312	cycle	cycle	B-NP	NN	O	33	NMOD	O
O	O	O	2313	2316	one	one	I-NP	CD	O	31	PMOD	O
O	O	O	2317	2325	compared	compare	B-PP	VBN	O	19	VMOD	O
O	O	O	2326	2330	with	with	B-PP	IN	O	34	PMOD	O
O	O	O	2331	2334	the	the	B-NP	DT	O	37	NMOD	O
O	O	O	2335	2343	baseline	baseline	I-NP	NN	O	35	PMOD	O
O	O	O	2343	2344	.	.	O	.	O	19	P	O

O	O	O	2345	2357	Correlations	Correlation	B-NP	NNS	O	35	SUB	O
O	O	O	2358	2360	of	of	B-PP	IN	O	1	NMOD	O
T18	B-Protein	B-Protein	2361	2368	TCRzeta	TCRzeta	B-NP	NN	B-protein	7	NMOD	B-protein
O	O	O	2369	2371	or	or	O	CC	O	7	NMOD	O
T19	B-Protein	B-Protein	2372	2375	p56	p56	B-NP	NN	B-protein	7	NMOD	B-protein
T19	I-Protein	I-Protein	2375	2376	(	(	O	(	I-protein	7	NMOD	I-protein
T19	I-Protein	I-Protein	2376	2379	lck	lck	B-NP	NN	I-protein	9	NMOD	I-protein
T19	I-Protein	I-Protein	2379	2380	)	)	O	)	I-protein	7	NMOD	I-protein
O	O	O	2381	2387	levels	level	B-NP	NNS	O	2	PMOD	O
O	O	O	2388	2392	with	with	B-PP	IN	O	1	NMOD	O
O	O	O	2393	2401	response	response	B-NP	NN	O	14	NMOD	O
O	O	O	2402	2404	or	or	I-NP	CC	O	14	NMOD	O
O	O	O	2405	2412	disease	disease	I-NP	NN	O	14	NMOD	O
O	O	O	2413	2422	variables	variable	I-NP	NNS	O	10	PMOD	O
O	O	O	2422	2423	,	,	O	,	O	1	P	O
O	O	O	2424	2430	except	except	B-PP	IN	O	1	NMOD	O
O	O	O	2431	2434	for	for	B-PP	IN	O	16	PMOD	O
O	O	O	2435	2440	lower	low	B-NP	JJR	O	20	NMOD	O
T20	B-Protein	B-Protein	2441	2448	TCRzeta	TCRzeta	I-NP	NN	B-protein	20	NMOD	B-protein
O	O	O	2449	2455	levels	level	I-NP	NNS	O	17	PMOD	O
O	O	O	2456	2457	(	(	O	(	O	27	DEP	O
O	O	O	2457	2458	P	P	B-NP	NN	O	27	DEP	O
O	O	O	2459	2460	<	<	B-ADJP	SYM	O	22	NMOD	O
O	O	O	2461	2462	0	0	B-NP	CD	O	23	AMOD	O
O	O	O	2462	2463	.	.	I-NP	.	O	22	P	O
O	O	O	2463	2466	001	001	I-NP	CD	O	22	NMOD	O
O	O	O	2466	2467	)	)	O	)	O	20	NMOD	O
O	O	O	2468	2470	in	in	B-PP	IN	O	1	NMOD	O
O	O	O	2471	2474	the	the	I-PP	DT	O	30	NMOD	O
O	O	O	2475	2483	presence	presence	I-PP	NN	O	28	PMOD	O
O	O	O	2484	2486	of	of	I-PP	IN	O	30	NMOD	O
O	O	O	2487	2491	bone	bone	B-NP	NN	B-protein	33	NMOD	B-protein
O	O	O	2492	2502	metastases	metastasis	I-NP	NNS	I-protein	31	PMOD	I-protein
O	O	O	2502	2503	,	,	O	,	O	1	P	O
O	O	O	2504	2508	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	2509	2512	not	not	I-VP	RB	O	35	VMOD	O
O	O	O	2513	2518	found	find	I-VP	VBN	O	35	VC	O
O	O	O	2518	2519	.	.	O	.	O	35	P	O

O	O	O	2520	2528	Abnormal	Abnormal	B-NP	JJ	O	3	NMOD	O
T35	B-Entity	B-Entity	2529	2537	NFkappaB	NFkappaB	I-NP	NN	B-protein	3	NMOD	B-protein
O	O	O	2538	2548	activation	activation	I-NP	NN	O	20	SUB	O
O	O	O	2549	2554	after	after	B-PP	IN	O	3	NMOD	O
O	O	O	2555	2566	stimulation	stimulation	B-NP	NN	O	4	PMOD	O
O	O	O	2567	2571	with	with	B-PP	IN	O	5	NMOD	O
O	O	O	2572	2579	phorbol	phorbol	B-NP	NN	O	11	NMOD	O
O	O	O	2580	2589	myristate	myristate	I-NP	NN	O	11	NMOD	O
O	O	O	2590	2597	acetate	acetate	I-NP	NN	O	11	NMOD	O
O	O	O	2597	2598	/	/	B-NP	SYM	O	11	NMOD	O
O	O	O	2598	2607	ionomycin	ionomycin	I-NP	NN	O	19	NMOD	O
O	O	O	2608	2611	and	and	O	CC	O	13	NMOD	O
O	O	O	2611	2612	/	/	B-NP	SYM	O	19	NMOD	O
O	O	O	2612	2614	or	or	O	CC	O	19	NMOD	O
O	O	O	2615	2619	anti	anti	B-NP	AFX	O	19	NMOD	O
O	O	O	2619	2620	-	-	I-NP	HYPH	O	19	NMOD	O
T36	B-Entity	B-Entity	2620	2623	CD3	CD3	I-NP	NN	B-protein	19	NMOD	B-protein
O	O	O	2624	2634	monoclonal	monoclonal	I-NP	JJ	I-protein	19	NMOD	I-protein
O	O	O	2635	2643	antibody	antibody	I-NP	NN	I-protein	6	PMOD	I-protein
O	O	O	2644	2647	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	2648	2653	found	find	I-VP	VBN	O	20	VC	O
O	O	O	2654	2656	in	in	B-PP	IN	O	21	VMOD	O
O	O	O	2657	2659	59	59	B-NP	CD	O	24	NMOD	O
O	O	O	2659	2660	%	%	I-NP	NN	O	22	PMOD	O
O	O	O	2661	2663	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	2664	2672	patients	patient	B-NP	NNS	O	25	PMOD	O
O	O	O	2673	2674	(	(	O	(	O	31	DEP	O
O	O	O	2674	2676	17	17	B-NP	CD	O	29	AMOD	O
O	O	O	2677	2679	of	of	B-PP	IN	O	31	DEP	O
O	O	O	2680	2682	28	28	B-NP	CD	O	29	AMOD	O
O	O	O	2682	2683	)	)	O	)	O	26	NMOD	O
O	O	O	2684	2687	and	and	O	CC	O	20	VMOD	O
O	O	O	2688	2691	was	be	B-VP	VBD	O	20	VMOD	O
O	O	O	2692	2695	not	not	I-VP	RB	O	33	VMOD	O
O	O	O	2696	2705	accounted	account	I-VP	VBN	O	33	VC	O
O	O	O	2706	2709	for	for	B-PP	IN	O	35	VMOD	O
O	O	O	2710	2712	by	by	B-PP	IN	O	36	PMOD	O
O	O	O	2713	2716	the	the	B-NP	DT	O	40	NMOD	O
O	O	O	2717	2725	advanced	advanced	I-NP	JJ	O	40	NMOD	O
O	O	O	2726	2729	age	age	I-NP	NN	O	37	PMOD	O
O	O	O	2730	2732	of	of	B-PP	IN	O	40	NMOD	O
O	O	O	2733	2736	the	the	B-NP	DT	O	44	NMOD	O
O	O	O	2737	2742	study	study	I-NP	NN	O	44	NMOD	O
O	O	O	2743	2749	cohort	cohort	I-NP	NN	O	41	PMOD	O
O	O	O	2749	2750	.	.	O	.	O	20	P	O

O	O	O	2751	2761	Activation	Activation	B-NP	NN	O	9	SUB	O
O	O	O	2762	2764	of	of	B-PP	IN	O	1	NMOD	O
T37	B-Entity	B-Entity	2765	2773	NFkappaB	NFkappaB	B-NP	NN	B-protein	2	PMOD	B-protein
O	O	O	2774	2776	in	in	B-PP	IN	O	1	NMOD	O
O	O	O	2777	2787	peripheral	peripheral	B-NP	JJ	B-cell_type	8	NMOD	B-cell_type
O	O	O	2788	2793	blood	blood	I-NP	NN	I-cell_type	8	NMOD	I-cell_type
O	O	O	2794	2795	T	T	I-NP	NN	I-cell_type	8	NMOD	I-cell_type
O	O	O	2796	2801	cells	cell	I-NP	NNS	I-cell_type	4	PMOD	I-cell_type
O	O	O	2802	2805	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	2806	2815	inducible	inducible	B-ADJP	JJ	O	9	PRD	O
O	O	O	2816	2822	during	during	B-PP	IN	O	9	VMOD	O
O	O	O	2823	2831	cytokine	cytokine	B-NP	NN	B-protein	13	NMOD	B-protein
O	O	O	2832	2839	therapy	therapy	I-NP	NN	O	11	PMOD	O
O	O	O	2840	2842	in	in	B-PP	IN	O	13	NMOD	O
O	O	O	2843	2847	four	four	B-NP	CD	O	18	NMOD	O
O	O	O	2848	2850	of	of	I-NP	IN	O	18	NMOD	O
O	O	O	2851	2854	six	six	I-NP	CD	O	18	NMOD	O
O	O	O	2855	2866	individuals	individual	I-NP	NNS	O	14	PMOD	O
O	O	O	2867	2870	who	who	B-NP	WP	O	18	NMOD	O
O	O	O	2871	2880	displayed	display	B-VP	VBD	O	19	SBAR	O
O	O	O	2881	2889	impaired	impaired	B-NP	JJ	O	23	NMOD	O
T38	B-Entity	B-Entity	2890	2898	NFkappaB	NFkappaB	I-NP	NN	B-protein	23	NMOD	B-protein
O	O	O	2899	2907	activity	activity	I-NP	NN	O	20	OBJ	O
O	O	O	2908	2913	prior	prior	B-ADVP	RB	O	25	PMOD	O
O	O	O	2914	2916	to	to	B-PP	TO	O	20	VMOD	O
O	O	O	2917	2924	therapy	therapy	B-NP	NN	O	25	PMOD	O
O	O	O	2924	2925	.	.	O	.	O	9	P	O

O	O	O	2926	2934	Moreover	Moreover	B-ADVP	RB	O	7	VMOD	O
O	O	O	2934	2935	,	,	O	,	O	7	P	O
O	O	O	2936	2944	impaired	impaired	B-NP	JJ	O	4	NMOD	O
O	O	O	2945	2955	activation	activation	I-NP	NN	O	7	SUB	O
O	O	O	2956	2958	of	of	B-PP	IN	O	4	NMOD	O
T39	B-Entity	B-Entity	2959	2967	NFkappaB	NFkappaB	B-NP	NN	B-protein	5	PMOD	B-protein
O	O	O	2968	2972	does	do	B-VP	VBZ	O	0	ROOT	O
O	O	O	2973	2976	not	not	I-VP	RB	O	7	VMOD	O
O	O	O	2977	2983	appear	appear	I-VP	VB	O	7	VC	O
O	O	O	2984	2990	linked	link	I-VP	VBN	O	9	OBJ	O
O	O	O	2991	2993	to	to	B-PP	TO	O	10	VMOD	O
O	O	O	2994	2995	a	a	B-NP	DT	O	13	NMOD	O
O	O	O	2996	3005	reduction	reduction	I-NP	NN	O	11	PMOD	O
O	O	O	3006	3008	of	of	B-PP	IN	O	13	NMOD	O
T21	B-Protein	B-Protein	3009	3016	TCRzeta	TCRzeta	B-NP	NN	B-protein	16	NMOD	B-protein
O	O	O	3017	3027	expression	expression	I-NP	NN	O	14	PMOD	O
O	O	O	3027	3028	,	,	O	,	O	7	P	O
O	O	O	3029	3036	because	because	B-SBAR	IN	O	7	VMOD	O
O	O	O	3037	3039	in	in	B-PP	IN	O	26	VMOD	O
O	O	O	3040	3044	five	five	B-NP	CD	O	21	NMOD	O
O	O	O	3045	3053	patients	patient	I-NP	NNS	O	19	PMOD	O
O	O	O	3053	3054	,	,	O	,	O	26	P	O
O	O	O	3055	3061	normal	normal	B-NP	JJ	O	25	NMOD	O
T22	B-Protein	B-Protein	3062	3069	TCRzeta	TCRzeta	I-NP	NN	B-protein	25	NMOD	B-protein
O	O	O	3070	3076	levels	level	I-NP	NNS	O	26	SUB	O
O	O	O	3077	3081	were	be	B-VP	VBD	O	18	SBAR	O
O	O	O	3082	3089	present	present	B-ADJP	JJ	O	26	PRD	O
O	O	O	3090	3098	although	although	B-SBAR	IN	O	26	VMOD	O
T40	B-Entity	B-Entity	3099	3105	kappaB	kappaB	B-NP	NN	B-protein	30	NMOD	B-protein
O	O	O	3106	3113	binding	binding	I-NP	NN	O	31	SUB	O
O	O	O	3114	3117	was	be	B-VP	VBD	O	28	SBAR	O
O	O	O	3118	3121	not	not	O	RB	O	31	VMOD	O
O	O	O	3122	3131	inducible	inducible	B-ADJP	JJ	O	31	PRD	O
O	O	O	3131	3132	.	.	O	.	O	7	P	O

O	O	O	3133	3135	In	In	B-PP	IN	O	14	VMOD	O
O	O	O	3136	3139	the	the	B-NP	DT	O	3	NMOD	O
O	O	O	3140	3148	majority	majority	I-NP	NN	O	1	PMOD	O
O	O	O	3149	3151	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	3152	3160	patients	patient	B-NP	NNS	O	4	PMOD	O
O	O	O	3161	3165	with	with	B-PP	IN	O	5	NMOD	O
O	O	O	3166	3174	advanced	advance	B-NP	VBN	O	8	NMOD	O
O	O	O	3175	3178	RCC	RCC	I-NP	NN	O	6	PMOD	O
O	O	O	3178	3179	,	,	O	,	O	14	P	O
O	O	O	3180	3190	peripheral	peripheral	B-NP	JJ	B-cell_type	13	NMOD	B-cell_type
O	O	O	3191	3196	blood	blood	I-NP	NN	I-cell_type	13	NMOD	I-cell_type
O	O	O	3197	3198	T	T	I-NP	NN	I-cell_type	13	NMOD	I-cell_type
O	O	O	3199	3204	cells	cell	I-NP	NNS	I-cell_type	14	SUB	I-cell_type
O	O	O	3205	3212	express	express	B-VP	VBP	O	0	ROOT	O
T23	B-Protein	B-Protein	3213	3220	TCRzeta	TCRzeta	B-NP	NN	B-protein	19	NMOD	B-protein
O	O	O	3221	3224	and	and	O	CC	O	19	NMOD	O
T24	B-Protein	B-Protein	3225	3228	p56	p56	B-NP	NN	B-protein	19	NMOD	B-protein
T24	I-Protein	I-Protein	3228	3229	(	(	O	(	I-protein	19	NMOD	I-protein
T24	I-Protein	I-Protein	3229	3232	lck	lck	B-NP	NN	I-protein	14	OBJ	I-protein
T24	I-Protein	I-Protein	3232	3233	)	)	O	)	I-protein	19	NMOD	I-protein
O	O	O	3233	3234	,	,	O	,	O	14	P	O
O	O	O	3235	3238	and	and	O	CC	O	14	VMOD	O
O	O	O	3239	3241	in	in	B-PP	IN	O	14	VMOD	O
O	O	O	3242	3243	a	a	B-NP	DT	O	25	NMOD	O
O	O	O	3244	3250	subset	subset	I-NP	NN	O	23	PMOD	O
O	O	O	3250	3251	,	,	O	,	O	14	P	O
O	O	O	3252	3259	reduced	reduce	B-VP	VBD	O	14	VMOD	O
O	O	O	3260	3266	levels	level	B-NP	NNS	O	27	OBJ	O
O	O	O	3267	3269	of	of	B-PP	IN	O	28	NMOD	O
O	O	O	3270	3275	these	these	B-NP	DT	O	33	NMOD	O
T25	B-Protein	B-Protein	3276	3283	TCRzeta	TCRzeta	I-NP	NN	B-protein	33	NMOD	B-protein
O	O	O	3284	3294	associated	associated	I-NP	JJ	I-protein	33	NMOD	I-protein
O	O	O	3295	3304	molecules	molecule	I-NP	NNS	I-protein	29	PMOD	I-protein
O	O	O	3305	3308	are	be	B-VP	VBP	O	27	VMOD	O
O	O	O	3309	3313	seen	see	I-VP	VBN	O	34	VC	O
O	O	O	3314	3318	that	that	B-NP	WDT	O	35	VMOD	O
O	O	O	3319	3322	may	may	B-VP	MD	O	36	SBAR	O
O	O	O	3323	3331	increase	increase	I-VP	VB	O	37	VC	O
O	O	O	3332	3338	during	during	B-PP	IN	O	38	VMOD	O
O	O	O	3339	3347	cytokine	cytokine	B-NP	NN	B-protein	43	NMOD	B-protein
O	O	O	3347	3348	-	-	O	HYPH	O	40	P	O
O	O	O	3348	3353	based	base	B-NP	VBN	O	43	NMOD	O
O	O	O	3354	3361	therapy	therapy	I-NP	NN	O	39	PMOD	O
O	O	O	3361	3362	.	.	O	.	O	14	P	O

O	O	O	3363	3371	Abnormal	Abnormal	B-NP	JJ	O	2	NMOD	O
O	O	O	3372	3382	activation	activation	I-NP	NN	O	5	SUB	O
O	O	O	3383	3385	of	of	B-PP	IN	O	2	NMOD	O
T41	B-Entity	B-Entity	3386	3394	NFkappaB	NFkappaB	B-NP	NN	B-protein	3	PMOD	B-protein
O	O	O	3395	3397	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	3398	3402	also	also	B-ADVP	RB	O	5	VMOD	O
O	O	O	3403	3410	present	present	B-ADJP	JJ	O	5	PRD	O
O	O	O	3411	3413	in	in	B-PP	IN	O	7	AMOD	O
O	O	O	3414	3415	>	>	B-NP	JJR	O	11	NMOD	O
O	O	O	3415	3417	50	50	I-NP	CD	O	11	NMOD	O
O	O	O	3417	3418	%	%	I-NP	NN	O	8	PMOD	O
O	O	O	3419	3421	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	3422	3430	patients	patient	B-NP	NNS	O	12	PMOD	O
O	O	O	3431	3434	and	and	O	CC	O	5	VMOD	O
O	O	O	3435	3438	may	may	B-VP	MD	O	5	VMOD	O
O	O	O	3439	3443	also	also	I-VP	RB	O	15	VMOD	O
O	O	O	3444	3450	revert	revert	I-VP	VB	O	15	VC	O
O	O	O	3451	3453	to	to	B-PP	TO	O	17	VMOD	O
O	O	O	3454	3460	normal	normal	B-ADJP	JJ	O	18	PMOD	O
O	O	O	3461	3467	during	during	B-PP	IN	O	17	VMOD	O
T26	B-Protein	B-Protein	3468	3470	IL	IL	B-NP	NN	B-protein	26	NMOD	B-protein
T26	I-Protein	I-Protein	3470	3471	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
T26	I-Protein	I-Protein	3471	3472	2	2	I-NP	CD	I-protein	26	NMOD	I-protein
O	O	O	3472	3473	/	/	I-NP	SYM	O	26	P	O
T27	B-Protein	B-Protein	3473	3476	IFN	IFN	I-NP	NN	B-protein	26	NMOD	B-protein
T27	I-Protein	I-Protein	3477	3482	alpha	alpha	B-NP	SYM	I-protein	29	NMOD	I-protein
O	O	O	3482	3483	-	-	B-VP	HYPH	O	29	NMOD	O
O	O	O	3483	3488	based	base	B-NP	VBN	O	29	NMOD	O
O	O	O	3489	3498	treatment	treatment	I-NP	NN	O	20	PMOD	O
O	O	O	3498	3499	.	.	O	.	O	5	P	O

O	O	O	3500	3504	This	This	B-NP	DT	O	2	NMOD	O
O	O	O	3505	3515	alteration	alteration	I-NP	NN	O	6	SUB	O
O	O	O	3516	3518	in	in	B-PP	IN	O	2	NMOD	O
T42	B-Entity	B-Entity	3519	3527	NFkappaB	NFkappaB	B-NP	NN	B-protein	5	NMOD	B-protein
O	O	O	3528	3538	activation	activation	I-NP	NN	O	3	PMOD	O
O	O	O	3539	3547	occurred	occur	B-VP	VBD	O	0	ROOT	O
O	O	O	3548	3550	in	in	B-PP	IN	O	6	VMOD	O
O	O	O	3551	3554	the	the	B-NP	DT	O	9	NMOD	O
O	O	O	3555	3563	presence	presence	I-NP	NN	O	7	PMOD	O
O	O	O	3564	3566	of	of	B-PP	IN	O	9	NMOD	O
O	O	O	3567	3573	normal	normal	B-NP	JJ	O	12	NMOD	O
O	O	O	3574	3584	expression	expression	I-NP	NN	O	10	PMOD	O
O	O	O	3585	3587	of	of	B-PP	IN	O	12	NMOD	O
T28	B-Protein	B-Protein	3588	3595	TCRzeta	TCRzeta	B-NP	NN	B-protein	18	NMOD	B-protein
O	O	O	3595	3596	-	-	O	HYPH	O	18	P	O
O	O	O	3596	3606	associated	associate	B-NP	VBN	O	18	NMOD	O
O	O	O	3607	3616	signaling	signaling	I-NP	NN	O	18	NMOD	O
O	O	O	3617	3625	elements	element	I-NP	NNS	O	13	PMOD	O
O	O	O	3625	3626	.	.	O	.	O	6	P	O

O	O	O	3627	3630	The	The	B-NP	DT	O	3	NMOD	O
O	O	O	3631	3639	clinical	clinical	I-NP	JJ	O	3	NMOD	O
O	O	O	3640	3652	significance	significance	I-NP	NN	O	7	SUB	O
O	O	O	3653	3655	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	3656	3661	these	these	B-NP	DT	O	6	NMOD	O
O	O	O	3662	3670	findings	finding	I-NP	NNS	O	4	PMOD	O
O	O	O	3671	3678	remains	remain	B-VP	VBZ	O	0	ROOT	O
O	O	O	3679	3686	unclear	unclear	B-ADJP	JJ	O	7	PRD	O
O	O	O	3686	3687	.	.	O	.	O	7	P	O
